STOCK TITAN

Centogene N.V. Common Shares - CNTG STOCK NEWS

Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.

Centogene N.V. (Nasdaq: CNTG) delivers cutting-edge solutions in genetic diagnostics and multiomic analysis for rare diseases. This news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements, financial developments, and strategic partnerships.

Access authoritative information about CNTG's diagnostic innovations, pharmaceutical collaborations, and biodatabank expansions. Our curated news collection features official press releases covering clinical study results, regulatory milestones, and business performance updates. Track the company's progress in translating genetic insights into precision medicine solutions.

Key updates include announcements about diagnostic test approvals, research publications, partnership agreements with biopharma leaders, and financial disclosures. All content is verified from primary sources to ensure accuracy and timeliness. The repository serves as a strategic resource for understanding Centogene's role in advancing rare disease research and treatment development.

Bookmark this page for streamlined access to Centogene's latest developments. Check back regularly to stay informed about critical updates affecting the company's position in genetic medicine and healthcare innovation.

Rhea-AI Summary

CENTOGENE has launched its validated COVID-19 test kit, CentoKit-19™, on Amazon in Germany, marking the first of its kind available through the platform. This testing solution aims to enhance access to COVID-19 testing, enabling individuals to receive results efficiently through digital reports. The test is validated according to WHO guidelines and offers a comprehensive at-home testing experience, including all necessary materials for sampling and return. The initiative supports public health efforts to manage the pandemic by facilitating early detection and breaking infection chains.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.1%
Tags
none
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) has announced the pricing of a public offering of 3,500,000 common shares at $14.00 each, aiming to raise $28 million for the company and $21 million for selling shareholders. The offering includes 2,000,000 shares from the company and 1,500,000 shares from shareholders. The underwriters have a 30-day option to purchase an additional 525,000 shares. Proceeds will support research and development for orphan drug initiatives, working capital, and potential acquisitions. The offering is set to close around July 14, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.09%
Tags
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) announced the publication of its paper titled ‘Rapid Large-Scale COVID-19 Testing During Shortages’ in Diagnostics. The study highlights innovative testing solutions amidst the COVID-19 pandemic, contributing valuable insights to the medical community. CEO Prof. Arndt Rolfs emphasized their commitment to high-quality molecular diagnostics, particularly in supporting widespread SARS-CoV-2 testing. The company aims to enhance patient care through reliable testing and has established a testing service at Frankfurt airport, reinforcing its role in addressing public health challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
covid-19
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) has initiated an underwritten public offering of 3.5 million common shares, consisting of 2 million shares from the company and 1.5 million from selling shareholders, with an additional 525,000 shares available for underwriters. Proceeds from the offering will fund research and development for orphan drug initiatives, working capital, and potential investments in complementary businesses. The offering is dependent on market conditions and a registration statement is pending effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.66%
Tags
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) has partnered with OESIS Network to provide COVID-19 screening for schools across the U.S. The partnership will utilize RT-PCR testing at affordable prices, aimed at facilitating the safe return of students and staff to campus. Up to 50,000 tests per week will be available, with potential for increased capacity. The initiative emphasizes privacy, utilizing anonymized sample collection. With a focus on quality and logistics, Centogene's services will support both public and independent schools, potentially funded through the Cares Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.96%
Tags
partnership covid-19
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) announced that the FDA has granted Emergency Use Authorization for its SARS-CoV-2 RT-PCR test. This test is designed for qualitative detection of the virus using upper respiratory samples. CEO Prof. Arndt Rolfs emphasized the company's commitment to high-quality diagnostics to combat COVID-19. The test, intended for use in CENTOGENE's certified laboratories in Germany, aims to facilitate early diagnosis and support public health initiatives. The company collaborates with pharmaceutical partners to enhance testing efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
covid-19
Rhea-AI Summary

CENTOGENE (NASDAQ: CNTG) has partnered exclusively with Lufthansa and Fraport to offer COVID-19 testing for passengers at Frankfurt Airport. This initiative aims to facilitate safe international travel as restrictions ease. The testing service is now available and will continue until July 31, 2021. Passengers can access a convenient walk-in testing center, obtaining results via a secure digital platform, essential for travels to countries requiring testing. This collaboration represents a significant step towards normalizing air travel amid the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
covid-19
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) announced the resignation of Supervisory Board member Christoph Ehlers, effective June 15, 2020, due to personal circumstances. Ehlers served over six years and contributed significantly to the company's growth. CEO Prof. Arndt Rolfs expressed gratitude for Ehlers' role and noted his ongoing involvement. Centogene specializes in rare diseases, leveraging real-world clinical and genetic data to aid patients and pharmaceutical companies, boasting a repository of 3.0 billion weighted data points from over 530,000 patients across 120 countries as of March 31, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) reported €12.1 million in revenues for Q1 2020, marking a 13% increase year-over-year. The company continues expanding its rare disease platform, with approximately 3 billion data points from over 530,000 patients. Despite the challenges posed by COVID-19, Centogene launched its CentoSwab™ testing kit and expanded testing capabilities. However, the company reported a comprehensive loss of €8.6 million, or €0.43 per share, compared to €5.2 million, or €0.33 per share, in Q1 2019. R&D and G&A expenses also increased significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) announced it will report its financial results for Q1 2020 on June 15, 2020. The earnings call will take place at 8 a.m. EST, where the company will discuss its financial performance and outlook. Centogene focuses on rare diseases, utilizing a platform that integrates clinical and genetic data from approximately 500,000 patients across 120 countries. The company collaborates with over 39 pharmaceutical partners to enhance orphan drug development. Interested participants can access the call by dialing provided numbers or via the company's Investor Relations webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
conferences earnings
Centogene N.V. Common Shares

Nasdaq:CNTG

CNTG Rankings

CNTG Stock Data

9.43M
29.00M
4.57%
66.89%
0.28%
Diagnostics & Research
Healthcare
Link
Germany
Rostock